Form 8-K BioXcel Therapeutics, For: May 10
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
BioXcel Therapeutics (BTAI) PT Raised to $128 at Truist Securities
May 10, 2021 12:13 PM EDTTruist Securities analyst Robyn Karnauskas raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $128.00 (from $127.00) while maintaining a Buy rating.
The analyst commented, "Key 1Q21 takeaways: 1) commercial US prep on track for '501 key indications launching 1Q22; 2) '501 EU market may provide... More
